Phelan-McDermid syndrome, bipolar disorder and treatment with lithium

被引:6
作者
Rowland, Tobias [1 ,2 ]
Pathania, Rani [2 ]
Roy, Ashok [2 ]
机构
[1] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England
[2] Coventry & Warwickshire Partnership Trust, Brooklands Hosp, Birmingham, W Midlands, England
关键词
22q13; 3; deletion; Bipolar Disorder; Lithium; Phelan-McDermid syndrome; DISABILITY; ONSET;
D O I
10.1111/bld.12235
中图分类号
G76 [特殊教育];
学科分类号
040109 ;
摘要
Accessible summary Phelan-McDermid syndrome is an uncommon genetic cause of intellectual disability, but should still be tested for. People with Phelan-McDermid syndrome may also suffer from bipolar disorder, and doctors should consider this diagnosis. We discuss two patients with both Phelan-McDermid Syndrome and bipolar disorder. Both patients improved when using a medication called lithium Doctors should consider using lithium in patients with Phelan-McDermid syndrome and evidence of bipolar disorder. Abstract Background Phelan-McDermid syndrome is caused by a deletion at chromosome 22q13.3, and results in a phenotype characterised by intellectual disability, features of autism, physical and mental health conditions. It is becoming increasingly recognised that bipolar disorder represents part of this phenotype. Materials and methods This case study describes 2 patients with Phelan-McDermid syndrome presenting with bipolar mania at inpatient unit for adults with intellectual disability. Both patients presented with severe disturbance of their behaviour, at times exhibiting aggression, disinhibition and hypersexuality. Results Despite treatment with a number of atypical antipsychotics and anticonvulsant mood stabilising agents, both patients showed the greatest improvement when started on lithium, and were successfully treated with this medication. Conclusions This adds further support to the growing evidence of bipolar disorder contributing to the phenotype of Phelan-McDermid syndrome, and clinicians should have a low threshold for considering the use of lithium in these patients.
引用
收藏
页码:202 / 205
页数:4
相关论文
共 15 条
  • [1] Phelan-McDermid Syndrome and SHANK3: Implications for Treatment
    Costales, Jesse L.
    Kolevzon, Alexander
    [J]. NEUROTHERAPEUTICS, 2015, 12 (03) : 620 - 630
  • [2] THE USE OF PSYCHOTROPIC MEDICATION IN PEOPLE WITH LEARNING-DISABILITY - TOWARDS RATIONAL PRESCRIBING
    DEB, S
    FRASER, W
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1994, 9 (04) : 259 - 272
  • [3] Neuropsychological phenotype and psychopathology in seven adult patients with Phelan-McDermid syndrome: implications for treatment strategy
    Egger, J. I. M.
    Zwanenburg, R. J.
    van Ravenswaaij-Arts, C. M. A.
    Kleefstra, T.
    Verhoeven, W. M. A.
    [J]. GENES BRAIN AND BEHAVIOR, 2016, 15 (04) : 395 - 404
  • [4] Egger J. I. M., 2017, BMJ CASE REPORTS, V2017, DOI 10. 1136/bcr-2017-220778
  • [5] The Emerging Role of SHANK Genes in Neuropsychiatric Disorders
    Guilmatre, Audrey
    Huguet, Guillaume
    Delorme, Richard
    Bourgeron, Thomas
    [J]. DEVELOPMENTAL NEUROBIOLOGY, 2014, 74 (02) : 113 - 122
  • [6] SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties
    Han, Kihoon
    Holder, J. Lloyd, Jr.
    Schaaf, Christian P.
    Lu, Hui
    Chen, Hongmei
    Kang, Hyojin
    Tang, Jianrong
    Wu, Zhenyu
    Hao, Shuang
    Cheung, Sau Wai
    Yu, Peng
    Sun, Hao
    Breman, Amy M.
    Patel, Ankita
    Lu, Hui-Chen
    Zoghbi, Huda Y.
    [J]. NATURE, 2013, 503 (7474) : 72 - +
  • [7] Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring
    Kolevzon, Alexander
    Angarita, Benjamin
    Bush, Lauren
    Wang, A. Ting
    Frank, Yitzchak
    Yang, Amy
    Rapaport, Robert
    Saland, Jeffrey
    Srivastava, Shubhika
    Farrell, Cristina
    Edelmann, Lisa J.
    Buxbaum, Joseph D.
    [J]. JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2014, 6
  • [8] Adult-Onset Psychosis and Clinical Genetics: A Case of Phelan-McDermid Syndrome
    Messias, Erick
    Kaley, Sean N.
    McKelvey, Kent D.
    [J]. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2013, 25 (04) : E27 - E27
  • [9] Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome
    Pasini, Augusto
    D'Agati, Elisa
    Casarelli, Livia
    Curatolo, Paolo
    [J]. BRAIN & DEVELOPMENT, 2010, 32 (05) : 425 - 427
  • [10] The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)
    Phelan, K.
    McDermid, H. E.
    [J]. MOLECULAR SYNDROMOLOGY, 2011, 2 (3-5) : 186 - 201